PROHIBITED AT ALL TIMES

NON-APPROVED SUBSTANCES

Any pharmacological substance which is not addressed by any of the subsequent sections of the List and with no current approval by any governmental regulatory health authority for human therapeutic use (e.g. drugs under pre-clinical or clinical development or discontinued, designer drugs, substances approved only for veterinary use) is prohibited at all times.

ANABOLIC AGENTS

1. ANABOLIC ANDROGENIC STEROIDS (AAS)

A. EXOGENOUS * AAS, INCLUDING:

1-androstenediol (5α-androst-1-ene-3β,17β-diol)
1-androstenedione (5α-androst-1-ene-3,17-dione)
1-androsterone (3α-hydroxy-5α-androst-1-ene-17-one)
1-testosterone (17β-hydroxy-5α-androst-1-en-3-one)
Bolasterone
Calusterone
Clostebol
Danazol ([1,2]oxazolo[4′,5′:2,3]pregna-4-en-20-yn-17α-ol)
Dehydrochlormethyltestosterone (4-chloro-17β-hydroxy-17α-methylandrosta-1,4-dien-3-one)
Desoxymethyltestosterone (17α-methyl-5α-androst-2-en-17β-ol and 17α-methyl-5α-androst-3-en-17β-ol )
Drostanolone
Ethylestrenol (19-norpregna-4-en-17α-ol)
Fluoxymesterone
Formebolone
Furazabol (17α-methyl [1,2,5]oxadiazolo[3′,4′:2,3]-5α-androstan-17β-ol)
Gestrinone
Mestanolone
Mesterolone
Metandienone (17β-hydroxy-17α-methylandrosta-1,4-dien-3-one)
Metenolone
Methandriol
Methasterone (17β-hydroxy-2α,17α-dimethyl-5α-androstan-3-one)
Methyldienolone (17β-hydroxy-17α-methylestra-4,9-dien-3-one)
Methyl-1-testosterone (17β-hydroxy-17α-methyl-5α-androst-1-en-3-one)
Methylnortestosterone (17β-hydroxy-17α-methylestr-4-en-3-one)
Methyltestosterone
Metribolone (methyltrienolone, 17β-hydroxy-17α-methylestra-4,9,11-trien-3-one)
Mibolerone
Norboletone
Norclostebol
Norethandrolone
Oxabolone
Oxandrolone
Oxymesterone
Oxymetholone
Prostanozol (17β-[(tetrahydropyran-2-yl)oxy]-1’H-pyrazolo[3,4:2,3]-5α-androstane)
Quinbolone
Stanozolol
Stanozolol
Stenbolone
Stenbolone
Tetrahydrogestrinone (17-hydroxy-18a-homo-19-nor-17α-pregna-4,9,11-trien-3-one)
Trenbolone (17β-hydroxyestr-4,9,11-trien-3-one)

and other substances with a similar chemical structure or similar biological effect(s).

B. ENDOGENOUS** AAS AND THEIR METABOLITES AND ISOMERS, WHEN ADMINISTERED EXOGENOUSLY, INCLUDING BUT NOT LIMITED TO:

4-androstenediol (androst-4-ene-3β,17β-diol)
4-hydroxytestosterone (4,17β-dihydroxyandrost-4-en-3-one)
5-androstenedione (androst-5-ene-3,17-dione)
7α-hydroxy-DHEA
7β-hydroxy-DHEA
7-keto-DHEA
19-norandrostenediol (estr-4-ene-3,17-diol)
19-norandrostenedione (estr-4-ene-3,17-dione)
Androstanolone (5α-dihydrotestosterone, 17β-hydroxy-5α-androstan-3-one)
Androstenediol (androst-5-ene-3β,17β-diol)
Androstenedione (androst-4-ene-3,17-dione)
Boldenone
Boldione (androsta-1,4-diene-3,17-dione)
Epiandrosterone (3β-hydroxy-5α-androstan-17-one)
Epi-dihydrotestosterone (17β-hydroxy-5β-androstan-3-one)
Epitestosterone
Nandrolone (19-nortestosterone)
Prasterone (dehydroepiandrosterone, DHEA, 3β-hydroxyandrost-5-en-17-one)
Testosterone

2. OTHER ANABOLIC AGENTS

Including, but not limited to:

Clenbuterol
Selective androgen receptor modulators (SARMs), e.g. andarine, LGD-4033, enobosarm (ostarine) and RAD140;
Tibolone
Zeranol
Zilpaterol

For purposes of this section: 
* “ exogenous” refers to a substance which is not ordinarily produced by the body naturally.
** “ endogenous” refers to a substance which is ordinarily produced by the body naturally.

PEPTIDE HORMONES, GROWTH FACTORS, RELATED SUBSTANCES AND MIMETICS

1. ERYTHROPOIETINS (EPO) AND AGENTS AFFECTING ERYTHROPOIESIS, INCLUDING, BUT NOT LIMITED TO:

1.1 ERYTHROPOIETIN-RECEPTOR AGONISTS, E.G.

Darbepoetins (dEPO)
Erythropoietins (EPO)
EPO based constructs (EPO-Fc, methoxy polyethylene glycol-epoetin beta (CERA))
EPO-mimetic agents and their constructs , e.g. CNTO-530, peginesatide;

1.2 HYPOXIA-INDUCIBLE FACTOR (HIF) ACTIVATING AGENTS, E.G.

Argon
Cobalt
Daprodustat (GSK1278863)
Molidustat
Roxadustat (FG-4592)
Vadadustat (AKB-6548)
Xenon

1.3 GATA INHIBITORS, E.G.

K-11706

1.4 TGF-BETA (TGF-Β) INHIBITORS, E.G.

Luspatercept
Sotatercept

1.5 INNATE REPAIR RECEPTOR AGONISTS, E.G.

Asialo EPO
Carbamylated EPO (CEPO)

2. PEPTIDE HORMONES AND THEIR RELEASING FACTORS

2.1 CHORIONIC GONADOTROPHIN (CG) AND LUTEINIZING HORMONE (LH) AND THEIR RELEASING FACTORS, IN MALES, E.G.

Buserelin
Deslorelin
Gonadorelin
Goserelin
Leuprorelin
Nafarelin
Triptorelin

2.2 CORTICOTROPHINS AND THEIR RELEASING FACTORS, E.G.

Corticorelin

2.3 GROWTH HORMONE (GH), ITS FRAGMENTS AND RELEASING FACTORS, INCLUDING, BUT NOT LIMITED TO:

Growth Hormone fragments , e.g. AOD-9604 and hGH 176-191;
Growth Hormone Releasing Hormone (GHRH), e.g. CJC-1293, CJC-1295, sermorelin and tesamorelin;
Growth Hormone Secretagogues (GHS), e.g. lenomorelin (ghrelin) and its mimetics, e.g. anamorelin, ipamorelin, macimorelin and tabimorelin;
GH-Releasing Peptides (GHRPs), e.g. alexamorelin, GHRP-1, GHRP-2 (pralmorelin), GHRP-3, GHRP-4, GHRP-5, GHRP-6, and examorelin (hexarelin);

3. GROWTH FACTORS AND GROWTH FACTOR MODULATORS, INCLUDING, BUT NOT LIMITED TO:

Fibroblast Growth Factors (FGFs)
Hepatocyte Growth Factor (HGF)
Insulin-like Growth Factor-1 (IGF-1), and its analogues;
Mechano Growth Factors (MGFs)
Platelet-Derived Growth Factor (PDGF)
Vascular-Endothelial Growth Factor (VEGF)
Thymosin-β4 , and its derivatives e.g. TB-500;

and other growth factors or growth factor modulators affecting muscle, tendon or ligament protein synthesis/degradation, vascularisation, energy utilization, regenerative capacity or fibre type switching.

BETA-2 AGONISTS

All selective and non-selective beta-2 agonists, including all optical isomers, are prohibited;

Including, but not limited to:

Fenoterol
Formoterol
Higenamine
Indacaterol
Olodaterol
Procaterol
Reproterol
Salbutamol
Salmeterol
Terbutaline
Tretoquinol (trimetoquinol)
Tulobuterol
Vilanterol

Except:

  • Inhaled salbutamol: maximum 1600 micrograms over 24 hours;
    in divided doses not to exceed 800 micrograms over 12 hours starting from any dose;
  • Inhaled formoterol: maximum delivered dose of 54 micrograms over 24 hours;
  • Inhaled salmeterol: maximum 200 micrograms over 24 hours.

The presence in urine of salbutamol in excess of 1000 ng/mL or formoterol in excess of 40 ng/mL is not consistent with therapeutic use of the substance and will be considered as an Adverse Analytical Finding (AAF) unless the Athlete proves, through a controlled pharmacokinetic study, that the abnormal result was the consequence of a therapeutic dose (by inhalation) up to the maximum dose indicated above.

HORMONE AND METABOLIC MODULATORS

The following hormone and metabolic modulators are prohibited:

1. Aromatase inhibitors including, but not limited to:

2-Androstenol (5α-androst-2-en-17-ol)
2-Androstenone (5α-androst-2-en-17-one)
3-Androstenol (5α-androst-3-en-17-ol)
3-Androstenone (5α-androst-3-en-17-one)
4-androstene-3,6,17 trione (6-oxo)
Aminoglutethimide
Anastrozole
Androsta-1,4,6-triene-3,17-dione (androstatrienedione)
Androsta-3,5-diene-7,17-dione (arimistane)
Exemestane
Formestane
Letrozole
Testolactone

2. Selective estrogen receptor modulators (SERMs) including, but not limited to:

Raloxifene
Tamoxifen
Toremifene

3. Other anti-estrogenic substances including, but not limited to:

Clomifene
Cyclofenil
Fulvestrant

4. Agents preventing activin receptor IIB activation including, but not limited, to:

Activin A-neutralizing antibodies
Activin receptor IIB competitors (e.g. decoy activin receptors (e.g. ACE-031))
Anti-activin receptor IIB antibodies (bimagrumab)
Myostatin inhibitors (myostatin-neutralizing antibodies (e.g. domagrozumab, landogrozumab, stamulumab), myostatin-binding proteins (e.g. follistatin, myostatin propeptide); agents reducing or ablating myostatin expression)

5. Metabolic modulators:

Activators of the AMP-activated protein kinase (AMPK), eg. AICAR, SR9009;
Peroxisome Proliferator Activated Receptor δ (PPARδ) agonists , e.g. 2-(2-methyl-4-((4-methyl-2-(4-(trifluoromethyl)phenyl)thiazol-5-yl)methylthio)phenoxy) acetic acid (GW1516, GW501516);
Insulins , and insulin-mimetics;
Meldonium
Trimetazidin

DIURETICS AND MASKING AGENTS

The following diuretics and masking agents are prohibited, as are other substances with a similar chemical structure or similar biological effect(s).

Including, but not limited to:

  • Desmopressin; probenecid; plasma expanders, e.g. intravenous administration of albumin, dextran, hydroxyethyl starch and mannitol.
  • Acetazolamide; amiloride; bumetanide; canrenone; chlortalidone; etacrynic acid; furosemide; indapamide; metolazone; spironolactone; thiazides, e.g. bendroflumethiazide, chlorothiazide and hydrochlorothiazide; triamterene and vaptans, e.g. tolvaptan.

Except:

  • Drospirenone; pamabrom; and ophthalmic use of carbonic anhydrase inhibitors (e.g. dorzolamide, brinzolamide).
  • Local administration of felypressin in dental anaesthesia.

The detection in an Athlete’s Sample at all times or In-Competition, as applicable, of any quantity of the following substances subject to threshold limits: formoterol, salbutamol, cathine, ephedrine, methylephedrine and pseudoephedrine, in conjunction with a diuretic or masking agent, will be considered as an Adverse Analytical Finding (AAF) unless the Athlete has an approved Therapeutic Use Exemption (TUE) for that substance in addition to the one granted for the diuretic or masking agent.

 

error: Content is protected !!